Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

56 questions · 56 findings · 1 reviews · Multiple Sclerosis and Rare Diseases of the CNS

No studies found 6 · 10.7%GRADE not reported 0 · 0%Very low 20 · 35.7%Low 17 · 30.4%Moderate 12 · 21.4%High 1 · 1.8%

Intervention not reported

Azathioprine (Direct evidence; 1 RCT; 59 participants) · Patients with RRMS Interventions: Azathioprine, daclizumab, fingolimod, glatiramer acetate, Immunoglobulins, interferon beta 1a ‐1b,…

It is very uncertain whether the intervention changes azathioprine (Direct evidence; 1 RCT; 59 participants) (very low certainty).

1 finding from 1 review

Intervention not reported

Azathioprine (Direct evidence; 1 RCT; 59 participants) · Patients with RRMS Interventions: Alemtuzumab, azathioprine, cladribine, dimethylfumarate, fingolimod, glatiramer acetate,…

It is very uncertain whether the intervention changes azathioprine (Direct evidence; 1 RCT; 59 participants) (very low certainty).

1 finding from 1 review

Intervention not reported

Azathioprine (Direct evidence; 1 RCT; 54 participants) · Patients with RRMS Interventions: Alemtuzumab, azathioprine, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate,…

It is very uncertain whether the intervention changes azathioprine (Direct evidence; 1 RCT; 54 participants) (very low certainty).

1 finding from 1 review

Intervention not reported

Azathioprine (Direct evidence; 1 RCT; 59 participants) · Patients with RRMS Interventions: alemtuzumab, azathriopine, cladribine, dimethylfumarate, fingolimod, glatiramer acetate,…

It is very uncertain whether the intervention changes azathioprine (Direct evidence; 1 RCT; 59 participants) (very low certainty).

1 finding from 1 review

Intervention not reported

Pegylated interferon beta‐1a (Direct evidence; 1 RCT; 1512 participants) · Patients with RRMS Interventions: Azathioprine, daclizumab, fingolimod, glatiramer acetate, Immunoglobulins, interferon beta 1a ‐1b,…

The intervention may leads to lower pegylated interferon beta‐1a (Direct evidence; 1 RCT; 1512… (low certainty).

1 finding from 1 review

Intervention not reported

Mitoxantrone (Direct evidence; 1 RCT; 51 participants) · Patients with RRMS Interventions: Azathioprine, daclizumab, fingolimod, glatiramer acetate, Immunoglobulins, interferon beta 1a ‐1b,…

The intervention may leads to lower mitoxantrone (Direct evidence; 1 RCT; 51 participants) (low certainty).

1 finding from 1 review

Intervention not reported

Natalizumab (Direct evidence; 1 RCT; 942 participants) · Patients with RRMS Interventions: Azathioprine, daclizumab, fingolimod, glatiramer acetate, Immunoglobulins, interferon beta 1a ‐1b,…

The intervention leads to lower natalizumab (Direct evidence; 1 RCT; 942 participants) (high certainty).

1 finding from 1 review

Intervention not reported

Teriflunomide (Direct evidence; 1 RCT; 1169 participants) · Patients with RRMS Interventions: Azathioprine, daclizumab, fingolimod, glatiramer acetate, Immunoglobulins, interferon beta 1a ‐1b,…

The intervention may leads to lower teriflunomide (Direct evidence; 1 RCT; 1169 participants) (low certainty).

1 finding from 1 review

Intervention not reported

Daclizumab (Direct evidence; 1 RCT; 621 participants) · Patients with RRMS Interventions: Azathioprine, daclizumab, fingolimod, glatiramer acetate, Immunoglobulins, interferon beta 1a ‐1b,…

The intervention probably leads to lower daclizumab (Direct evidence; 1 RCT; 621 participants) (moderate certainty).

1 finding from 1 review

Intervention not reported

Cladribine (Direct evidence; 1 RCT; 1326 participants) · Patients with RRMS Interventions: Alemtuzumab, azathioprine, cladribine, dimethylfumarate, fingolimod, glatiramer acetate,…

The intervention may leads to lower cladribine (Direct evidence; 1 RCT; 1326 participants) (low certainty).

1 finding from 1 review

Intervention not reported

Dimethylfumarate (Direct evidence; 2 RCTs; 2307 participants) · Patients with RRMS Interventions: Alemtuzumab, azathioprine, cladribine, dimethylfumarate, fingolimod, glatiramer acetate,…

The intervention may leads to lower dimethylfumarate (Direct evidence; 2 RCTs; 2307 participants) (low certainty).

1 finding from 1 review

Intervention not reported

Fingolimod No direct evidence · Patients with RRMS Interventions: Azathioprine, daclizumab, fingolimod, glatiramer acetate, Immunoglobulins, interferon beta 1a ‐1b,…

The intervention probably leads to lower fingolimod No direct evidence (moderate certainty).

1 finding from 1 review

Intervention not reported

Fingolimod (Direct evidence; 2 RCTs; 2355 participants) · Patients with RRMS Interventions: Alemtuzumab, azathioprine, cladribine, dimethylfumarate, fingolimod, glatiramer acetate,…

The intervention may leads to lower fingolimod (Direct evidence; 2 RCTs; 2355 participants) (low certainty).

1 finding from 1 review

Intervention not reported

Glatiramer acetate (Direct evidence; 3 RCTs; 1014 participants) · Patients with RRMS Interventions: Alemtuzumab, azathioprine, cladribine, dimethylfumarate, fingolimod, glatiramer acetate,…

It is very uncertain whether the intervention changes glatiramer acetate (Direct evidence; 3 RCTs; 1014 participants) (very low certainty).

1 finding from 1 review

Intervention not reported

Immunoglobulins (Direct evidence; 2 RCTs; 190 participants) · Patients with RRMS Interventions: Alemtuzumab, azathioprine, cladribine, dimethylfumarate, fingolimod, glatiramer acetate,…

It is very uncertain whether the intervention changes immunoglobulins (Direct evidence; 2 RCTs; 190 participants) (very low certainty).

1 finding from 1 review

Intervention not reported

Interferon beta 1a‐1b No direct evidence · Patients with RRMS Interventions: Alemtuzumab, azathioprine, cladribine, dimethylfumarate, fingolimod, glatiramer acetate,…

It is very uncertain whether the intervention changes interferon beta 1a‐1b No direct evidence (very low certainty).

1 finding from 1 review